Wall Street analysts predict that PRA Health Sciences Inc (NASDAQ:PRAH) will post sales of $764.34 million for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for PRA Health Sciences’ earnings, with the lowest sales estimate coming in at $758.00 million and the highest estimate coming in at $777.20 million. PRA Health Sciences posted sales of $722.84 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 5.7%. The firm is scheduled to issue its next earnings results on Wednesday, August 7th.

On average, analysts expect that PRA Health Sciences will report full year sales of $3.10 billion for the current year, with estimates ranging from $3.08 billion to $3.15 billion. For the next year, analysts forecast that the company will report sales of $3.39 billion, with estimates ranging from $3.32 billion to $3.45 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for PRA Health Sciences.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings data on Wednesday, February 27th. The medical research company reported $1.21 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.18 by $0.03. The firm had revenue of $729.65 million for the quarter, compared to analyst estimates of $750.67 million. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%.

Several research firms have weighed in on PRAH. BidaskClub lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, April 10th. ValuEngine lowered shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, April 13th. Wolfe Research began coverage on shares of PRA Health Sciences in a research note on Tuesday, April 2nd. They issued a “market perform” rating on the stock. Mizuho set a $100.00 price objective on shares of PRA Health Sciences and gave the company a “hold” rating in a research note on Friday, May 3rd. Finally, Robert W. Baird upped their price objective on shares of PRA Health Sciences from $119.00 to $122.00 and gave the company an “outperform” rating in a research note on Thursday, February 28th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $113.22.

Several institutional investors and hedge funds have recently made changes to their positions in PRAH. BlackRock Inc. boosted its holdings in shares of PRA Health Sciences by 0.9% during the 1st quarter. BlackRock Inc. now owns 6,211,391 shares of the medical research company’s stock worth $685,054,000 after buying an additional 52,524 shares during the period. Vanguard Group Inc lifted its stake in PRA Health Sciences by 12.8% in the third quarter. Vanguard Group Inc now owns 5,811,972 shares of the medical research company’s stock valued at $640,421,000 after buying an additional 658,191 shares in the last quarter. FMR LLC lifted its stake in PRA Health Sciences by 11.3% in the first quarter. FMR LLC now owns 2,881,740 shares of the medical research company’s stock valued at $317,827,000 after buying an additional 292,887 shares in the last quarter. AQR Capital Management LLC lifted its stake in PRA Health Sciences by 48.7% in the first quarter. AQR Capital Management LLC now owns 1,825,143 shares of the medical research company’s stock valued at $199,032,000 after buying an additional 597,699 shares in the last quarter. Finally, Frontier Capital Management Co. LLC lifted its stake in PRA Health Sciences by 2.8% in the first quarter. Frontier Capital Management Co. LLC now owns 896,923 shares of the medical research company’s stock valued at $98,922,000 after buying an additional 24,207 shares in the last quarter. Institutional investors own 99.09% of the company’s stock.

PRA Health Sciences stock traded up $0.47 during trading hours on Friday, hitting $87.72. The company had a trading volume of 778,700 shares, compared to its average volume of 529,052. The firm has a market cap of $5.69 billion, a PE ratio of 22.32, a P/E/G ratio of 1.16 and a beta of 1.01. The company has a debt-to-equity ratio of 0.97, a quick ratio of 0.90 and a current ratio of 0.90. PRA Health Sciences has a fifty-two week low of $80.28 and a fifty-two week high of $121.98.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Recommended Story: What is the NASDAQ Stock Market?

Get a free copy of the Zacks research report on PRA Health Sciences (PRAH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.